Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker BIIB · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Ag… NCT07444476 · Spinal Muscular Atrophy Salanersen | BIIB Biogen | Phase 3 | Recruiting | 90 | Jun 23, 2028 | Registry ↗ |
| Nov 12, 2026 | A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Scl… NCT07855211 · Amyotrophic Lateral Sclerosis BIIB147, Placebo | BIIB Biogen | Phase 1/2 | Recruiting | 69 | Jan 23, 2034 | Registry ↗ |
| Nov 12, 2026 | A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With… NCT07722546 · Graves' Disease Felzartamab, Placebo | BIIB Biogen | Phase 2 | Recruiting | 60 | Jan 31, 2028 | Registry ↗ |
| Nov 12, 2026 | A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Asse… NCT05925049 · Multiple Sclerosis Natalizumab | BIIB Biogen | — | Completed was active, not recruiting | 271 | Oct 29, 2026 | Registry ↗ |
| Nov 12, 2026 | A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA)… NCT05789758 · Muscular Atrophy, Spinal No Intervention | BIIB Biogen | — | Recruiting | 20 | Oct 31, 2032 | Registry ↗ |
| Nov 9, 2026 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary… NCT06962800 · Primary Membranous Nephropathy Felzartamab, Tacrolimus | BIIB Biogen | Phase 3 | Recruiting | 180 | Jan 28, 2030 | Registry ↗ |
| Nov 5, 2026 | A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who H… NCT07219043 · Microvascular Inflammation Felzartamab, Placebo | BIIB Biogen | Phase 2 | Recruiting | 81 | Feb 10, 2028 | Registry ↗ |
| Nov 4, 2026 | Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a S… NCT04856982 · Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene M… Tofersen, Placebo | BIIB Biogen | Phase 3 | Active, not recruiting | 158 | Aug 7, 2027 | Registry ↗ |
| Nov 2, 2026 | A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults Wit… NCT07444489 · Antibody-mediated Rejection, Microvascular Inflammation Felzartamab | BIIB Biogen | Phase 3 | Enrolling by invitation | 201 | Dec 31, 2031 | Registry ↗ |
| Oct 30, 2026 | A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spin… NCT04488133 · Muscular Atrophy, Spinal Nusinersen | BIIB Biogen | Phase 4 | Completed | 46 | Oct 9, 2025 | Registry ↗ |
| Oct 26, 2026 | A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclero… NCT05767736 · Multiple Sclerosis Diroximel Fumarate, Dimethyl Fumarate | BIIB Biogen | — | Active, not recruiting | 10,500 | Dec 1, 2032 | Registry ↗ |
| Oct 26, 2026 | A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living… NCT04317794 · Muscular Atrophy, Spinal Nusinersen Sodium Injection | BIIB Biogen | — | Active, not recruiting | 74 | Feb 5, 2027 | Registry ↗ |
| Oct 23, 2026 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before… NCT07221669 · Muscular Atrophy, Spinal Salanersen | BIIB Biogen | Phase 3 | Recruiting | 30 | Nov 28, 2028 | Registry ↗ |
| Oct 23, 2026 | A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies… NCT05575011 · Healthy Volunteer, Muscular Atrophy, Spinal BIIB115, BIIB115-Matching Placebo | BIIB Biogen | Phase 1 | Active, not recruiting | 62 | Nov 14, 2031 | Registry ↗ |
| Oct 23, 2026 | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Part… NCT05531565 · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous L… Litifilimab, Placebo | BIIB Biogen | Phase 2/3 | Active, not recruiting | 450 | Oct 20, 2026 | Registry ↗ |
| Oct 22, 2026 | A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Ne… NCT07889362 · Immunoglobulin A Nephropathy Felzartamab | BIIB Biogen | Phase 2 | Not yet recruiting | 25 | Aug 13, 2028 | Registry ↗ |
| Oct 21, 2026 | A Study to Learn More About Friedrich's Ataxia in People Living in the Gulf Cooperation Council (GC… NCT07887828 · Friedreich's Ataxia | BIIB Biogen | — | Not yet recruiting | 40 | Jan 1, 2029 | Registry ↗ |
| Oct 15, 2026 | A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spi… NCT07444450 · Muscular Atrophy, Spinal Salanersen, Sham Procedure | BIIB Biogen | Phase 3 | Recruiting | 42 | Jul 27, 2029 | Registry ↗ |
| Oct 15, 2026 | A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took i… NCT05688436 · Multiple Sclerosis Diroximel Fumarate, Alemtuzumab | BIIB Biogen | — | Active, not recruiting | 1,178 | Jan 17, 2031 | Registry ↗ |
| Oct 14, 2026 | A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephrop… NCT06935357 · Immunoglobulin A Nephropathy (IgAN) Felzartamab, Placebo | BIIB Biogen | Phase 3 | Recruiting | 454 | May 31, 2027 | Registry ↗ |
| Oct 5, 2026 | A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effec… NCT05352919 · Systemic Lupus Erythematosus (SLE) Litifilimab, Litifilimab-matching placebo | BIIB Biogen | Phase 3 | Enrolling by invitation | 864 | May 3, 2032 | Registry ↗ |
| Oct 2, 2026 | A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children… NCT06953583 · Friedreich Ataxia Omaveloxolone, Placebo | BIIB Biogen | Phase 3 | Active, not recruiting | 255 | Nov 16, 2027 | Registry ↗ |
| Sep 24, 2026 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pe… NCT03958877 · Multiple Sclerosis, Relapsing-Remitting BIIB017 (peginterferon beta-1a), Interferon beta type 1a | BIIB Biogen | Phase 3 | Active, not recruiting | 152 | May 20, 2027 | Registry ↗ |
| Sep 11, 2026 | Pediatric Spinal Muscular Atrophy (SMA) China Registry NCT05042921 · Muscular Atrophy, Spinal | BIIB Biogen | — | Active, not recruiting | 600 | Sep 2, 2027 | Registry ↗ |
| Sep 8, 2026 | A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting… NCT07398469 · Postpartum Depression Zuranolone | BIIB Biogen | — | Recruiting | 300 | Mar 29, 2027 | Registry ↗ |
| Sep 8, 2026 | A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants W… NCT07047820 · Depression, Postpartum Zuranolone | BIIB Biogen | — | Completed | 305 | Aug 2, 2026 | Registry ↗ |
| Sep 3, 2026 | A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ S… NCT06555419 · Muscular Atrophy, Spinal Nusinersen, ThecaFlex DRx System | BIIB Biogen | Phase 1 | Recruiting | 78 | Sep 30, 2027 | Registry ↗ |
| Sep 3, 2026 | A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About It… NCT06054893 · Friedreich Ataxia Omaveloxolone | BIIB Biogen | Phase 1 | Active, not recruiting | 33 | Jun 4, 2030 | Registry ↗ |
| Sep 3, 2026 | A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 Wi… NCT02255435 · Friedreich Ataxia Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg | BIIB Biogen | Phase 2 | Completed | 172 | Oct 31, 2019 | Registry ↗ |
| Aug 13, 2026 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With… NCT07223723 · Amyotrophic Lateral Sclerosis Tofersen | BIIB Biogen | Phase 4 | Active, not recruiting | 12 | May 26, 2027 | Registry ↗ |
| Aug 11, 2026 | Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) NCT05658497 · Multiple Sclerosis Diroximel Fumarate, Avonex | BIIB Biogen | — | Recruiting | 908 | Jul 6, 2032 | Registry ↗ |
| Aug 11, 2026 | A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Inject… NCT04729907 · Muscular Atrophy, Spinal Nusinersen | BIIB Biogen | Phase 3 | Completed | 115 | Jul 30, 2026 | Registry ↗ |
| Aug 4, 2026 | A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and… NCT06044337 · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous L… BIIB059 (litifilimab) | BIIB Biogen | Phase 3 | Enrolling by invitation | 306 | Jun 26, 2029 | Registry ↗ |
| Aug 4, 2026 | Adult Spinal Muscular Atrophy (SMA) China Registry NCT05618379 · Muscular Atrophy, Spinal | BIIB Biogen | — | Active, not recruiting | 200 | Jun 1, 2028 | Registry ↗ |
| Jul 27, 2026 | A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the B… NCT07662148 · Healthy Volunteer BIIB144, Placebo | BIIB Biogen | Phase 1 | Recruiting | 48 | Jun 19, 2028 | Registry ↗ |
| Jul 10, 2026 | A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's At… NCT06628687 · Friedreich Ataxia Omaveloxolone | BIIB Biogen | — | Recruiting | 10 | Apr 30, 2035 | Registry ↗ |
| Jul 10, 2026 | A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled D… NCT06454721 · Healthy Volunteer [89Zr]Zr-DFO-Diranersen, Diranersen | BIIB Biogen | Phase 1 | Completed | 5 | Mar 5, 2026 | Registry ↗ |
| Jun 30, 2026 | A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve S… NCT05399888 · Mild Cognitive Impairment Due to Alzheimer's Disease, Alzhe… Diranersen, Diranersen-matching placebo | BIIB Biogen | Phase 2 | Active, not recruiting | 416 | Mar 11, 2026 | Registry ↗ |
| Jun 5, 2026 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney T… NCT06685757 · Antibody-mediated Rejection Felzartamab, Placebo | BIIB Biogen | Phase 3 | Active, not recruiting | 132 | Dec 1, 2026 | Registry ↗ |
| Jun 4, 2026 | A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Ear… NCT05348785 · Parkinson Disease BIIB122, BIIB122-Matching Placebo | BIIB Biogen | Phase 2 | Completed | 650 | Mar 9, 2026 | Registry ↗ |
| May 26, 2026 | A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Und… NCT06741657 · Healthy Volunteer Litifilimab, AI | BIIB Biogen | Phase 1 | Completed | 404 | Mar 10, 2026 | Registry ↗ |
| May 22, 2026 | A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Pa… NCT05067790 · Spinal Muscular Atrophy Nusinersen | BIIB Biogen | Phase 3 | Active, not recruiting | 45 | Sep 24, 2027 | Registry ↗ |
| May 19, 2026 | Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Mul… NCT02283853 · Relapsing-Remitting Multiple Sclerosis dimethyl fumarate, Interferon β-1a | BIIB Biogen | Phase 3 | Completed | 156 | Jul 8, 2025 | Registry ↗ |
| May 14, 2026 | A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tab… NCT07297199 · Healthy Volunteer Omaveloxolone | BIIB Biogen | Phase 1 | Completed | 70 | May 1, 2026 | Registry ↗ |
| May 6, 2026 | A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult P… NCT07133828 · Healthy Volunteer BIIB142, BIIB142-Matching Placebo | BIIB Biogen | Phase 1 | Recruiting | 78 | Aug 6, 2026 | Registry ↗ |
| Apr 28, 2026 | A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Fr… NCT06623890 · Friedreich Ataxia Omaveloxolone | BIIB Biogen | — | Recruiting | 300 | Oct 1, 2029 | Registry ↗ |
| Apr 9, 2026 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superox… NCT07259980 · Amyotrophic Lateral Sclerosis Tofersen | BIIB Biogen | — | Recruiting | 125 | Dec 30, 2033 | Registry ↗ |
| Mar 19, 2026 | A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their… NCT07483632 · Relapsing Forms of Multiple Sclerosis Diroximel Fumarate, Dimethyl Fumarate | BIIB Biogen | Phase 3 | Not yet recruiting | 185 | Jul 28, 2034 | Registry ↗ |
| Feb 20, 2026 | A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone… NCT05798520 · Relapsing Forms of Multiple Sclerosis BIIB091, DRF | BIIB Biogen | Phase 2 | Completed | 127 | Feb 10, 2026 | Registry ↗ |
| Feb 10, 2026 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve… NCT04895241 · Lupus Erythematosus, Systemic Litifilimab, Placebo | BIIB Biogen | Phase 3 | Active, not recruiting | 548 | Sep 30, 2026 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:08 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances